Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
University of California, San Francisco | San Francisco, California | United States | about 1 month ago
the laboratory. Our research is primarily focused on: 1) chronic hypoxia sensing and adaptation, and 2) mechanisms of cardiovascular complications from cancer-directed therapies. We seek to understand how cells
-
, families, and a dedicated healthcare team. Common Therapies Provided: Blood and blood product transfusions Emerging therapies, complex infusion therapies, and gene therapies Metabolic enzyme replacement
-
. Unfortunately, around 50% of these individuals are unable to benefit from current or emerging treatments such as gene or stem cell therapies, pharmaceuticals, or retinal prostheses. Although cortical
-
, Germany offers a PhD position for a doctoral candidate/MSCA fellow for the project: “The effect of bioidentical MHT on ER as a transdiagnostic factor for mental health in women during menopause transition
-
research experiments as defined by the PI. The Ling Lab Our lab focuses on developing gene therapies for diseases associated with mitochondrial dysfunctions. Currently, we are focusing on diseases including
-
of Coimbra, with the ambition of developing innovative platforms incorporating therapeutic agents (e.g., nucleic acids, small molecules, peptides), involving mRNA for gene therapy. In the context
-
About your role Orion Pharma is making strategic investments in challenging R&D areas where our expertise can drive breakthroughs—particularly in cancer therapies. As part of this commitment, we
-
the University of Basel and the University Hospitals Basel. It unites basic and clinical scientists to advance our understanding of health and disease and to develop pioneering therapies benefiting
-
Leibniz-Institute for Food Systems Biology at the Technical University of Munich | Freising, Bayern | Germany | 18 days ago
, combining chemistry, photonics, and molecular biology, and has direct implications for DNA data storage, gene therapy, genome screening, proteomics, and genomics. The goal is to push the limits of DNA
-
to decode and harness noncoding variant contributors to cardiomyopathy. We have also developed two new mouse models for translational discovery and testing of gene therapy approaches (novel haploinsufficient